SCHEMBL14949561

SCHEMBL14949561

Cc1ccc2c(Oc3ccc(-c4nnc(Nc5cccc(C(F)(F)F)c5)[nH]4)cc3)ccnc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 9/20 0.48
KDR P35968 4/20 0.48
MAPK14 Q16539 3/20 0.48
TNNI3K Q59H18 2/20 0.48
RAF1 P04049 1/20 0.41
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40
HTT P42858 1/20 0.39
PDGFRA P16234 2/20 0.39
FGFR2 P21802 2/20 0.38
EGFR P00533 1/20 0.38
ABCG2 Q9UNQ0 1/20 0.38
PDGFRB P09619 1/20 0.38
KIT P10721 1/20 0.38
CDK11B P21127 1/20 0.38
FLT3 P36888 1/20 0.38
CDKL2 Q92772 1/20 0.38
GAK O14976 1/20 0.38
AXL P30530 1/20 0.38
PHGDH O43175 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12336392 0.93 BRAF (0.48) BRAFKDRMAPK14TNNI3KRAF1
SCHEMBL12336222 0.93 BRAF (0.51) BRAFKDRMAPK14TNNI3KRAF1
SCHEMBL14949575 0.92 BRAF (0.43) BRAFKDRMAPK14TNNI3KRAF1
SCHEMBL12336406 0.92 GSK3A (0.50) BRAFKDRMAPK14TNNI3KRAF1
SCHEMBL14949581 0.91 BRAF (0.51) BRAFKDRMAPK14TNNI3KRAF1
SCHEMBL14949208 0.90 KDR (0.46) KDRPDGFRAFGFR2EGFRAXL
SCHEMBL12336224 0.90 BRAF (0.48) BRAFKDRMAPK14TNNI3KRAF1
SCHEMBL12336399 0.90 BRAF (0.48) BRAFKDRMAPK14TNNI3KRAF1
SCHEMBL14949484 0.90 BRAF (0.60) BRAFKDRMAPK14TNNI3KRAF1
SCHEMBL16788759 0.88 KDR (0.55) BRAFKDRMAPK14TNNI3KPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9212151-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-12-15 US disclosed
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2015-06-11 US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 BRAF 39/4885KDR 533/4885MAPK14 90/4885
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 BRAF 39/4885KDR 533/4885MAPK14 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.